[1] FAHAD ULLAH M.Breast cancer:current perspectives on the disease status[J].Adv Exp Med Biol, 2019, 1152:51.
[2] LETO G.Current status and future directions in the treatment of bone metastases from breast cancer[J].Clin Exp Pharmacol Physiol, 2019, 46(10):968. doi: 10.1111/1440-1681.13139
[3] LIN X, HONG S, CHEN J, et al.The potential targets for metastases:a study on altered circular RNA profile in breast cancer liver metastases[J].Epigenomics, 2019, 1750:1911.
[4] ZHANG T, LIP H, HE C, et al.Multitargeted nanoparticles deliver synergistic drugs across the blood-brain barrier to brain metastases of triple negative breast cancer cells and tumor-associated macrophages[J].Adv Healthc Mater, 2019, 8(18):e1900543. doi: 10.1002/adhm.201900543
[5] GADALLA R, HASSAN H, IBRAHIM SA, et al.Tumor microenvironmental plasmacytoid dendritic cells contribute to breast cancer lymph node metastasis via CXCR4/SDF-1 axis[J].Breast Cancer Res Treat, 2019, 174(3):679.
[6] ALQAHTANI FY, ALEANIZY FS, EL TAHIR E, et al.Paclitaxel[J].Profiles Drug Subst Excip Relat Methodol, 2019, 44:205. doi: 10.1016/bs.podrm.2018.11.001
[7] BAKRANIA AK, VARIYA BC, PATEL SS.Novel targets for paclitaxel nano formulations:hopes and hypes in triple negative breast cancer[J].Pharmacol Res, 2016, 111:577. doi: 10.1016/j.phrs.2016.07.023
[8] LIU Y, NG Y, TOH MR, et al.Lipid-dendrimer hybrid nanosystem as a novel delivery system for paclitaxel to treat ovarian cancer[J].J Control Release, 2015, 220(Pt A):438.
[9] HASSAN MS, AWASTHI N, LI J, et al.Superior therapeutic efficacy of nanoparticle albumin bound paclitaxel over cremophor-bound paclitaxel in experimental esophageal adenocarcinoma[J].Transl Oncol, 2018, 11(2):426.
[10] ERICA G, THOMAS LS.The paradox of paclitaxel neurotoxicity:mechanisms and unanswered questions[J].Neuropharmacology, 2013, 76(1):175.
[11] SARISOZEN C, VURAL I, LEVCHENKO T, et al.PEG-PE-based micelles co-loaded with taxol and cyclosporine A or loaded with taxol and targeted by anticancer antibody overcome drug resistance in cancer cells[J].Drug Deliv, 2012, 19(4):169. doi: 10.3109/10717544.2012.674163
[12] HUANG L, CHEN H, ZHENG Y, et al.Nanoformulation of D-α-tocopheryl polyethylene glycol 1000 succinate-b-poly (ε-caprolactone-ran-glycolide) diblock copolymer for breast cancer therapy[J].Integr Biol(Camb), 2011, 3(10):993.
[13] ZHANG Z, TAN S, FENG SS.Vitamin E TPGS as a molecular biomaterial for drug delivery[J].Biomaterials, 2012, 33(19):4889. doi: 10.1016/j.biomaterials.2012.03.046
[14] WANG Q, ZHANG P, LI Z, et al.Evaluation of polymer nanoformulations in hepatoma therapy by established rodent models[J].Theranostics, 2019, 9(5):1426. doi: 10.7150/thno.31683
[15] DAI W, JIN W, ZHANG J, et al.Spatiotemporally controlled co-delivery of anti-vasculature agent and cytotoxic drug by octreotide-modified stealth liposomes[J].Pharm Res, 2012, 29(10):2902. doi: 10.1007/s11095-012-0797-2
[16] KIM DH, IM BN, HWANG HS, et al.Gemcitabine-loaded DSPE-PEG-PheoA liposome as a photomediated immune modulator for cholangiocarcinoma treatment[J].Biomaterials, 2018, 183:139. doi: 10.1016/j.biomaterials.2018.08.052